REPLReplimune Group, Inc.

Nasdaq replimune.com


$ 7.15 $ 1.35 (23.28 %)    

Thursday, 06-Jun-2024 15:52:47 EDT
QQQ $ 463.39 $ -0.29 (-0.06 %)
DIA $ 389.23 $ 0.52 (0.13 %)
SPY $ 534.36 $ -0.61 (-0.11 %)
TLT $ 93.24 $ 0.36 (0.38 %)
GLD $ 219.35 $ 1.51 (0.7 %)
$ 5.56
$ 5.80
$ 7.13 x 212
$ 0.00 x 0
$ 5.80 - $ 7.24
$ 4.92 - $ 24.81
951,257
na
370.13M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-16-2024 03-31-2024 10-K
2 02-08-2024 12-31-2023 10-Q
3 11-07-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-18-2023 03-31-2023 10-K
6 02-09-2023 12-31-2022 10-Q
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-19-2022 03-31-2022 10-K
10 02-03-2022 12-31-2021 10-Q
11 11-04-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 05-20-2021 03-31-2021 10-K
14 02-04-2021 12-31-2020 10-Q
15 11-05-2020 09-30-2020 10-Q
16 08-07-2020 06-30-2020 10-Q
17 06-03-2020 03-31-2020 10-K
18 02-13-2020 12-31-2019 10-Q
19 11-12-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 06-28-2019 03-31-2019 10-K
22 02-14-2019 12-31-2018 10-Q
23 11-14-2018 09-30-2018 10-Q
24 08-30-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-mid-cap-cancer-focused-replimune-stock-trading-higher-on-thursday

Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rat...

 replimune-to-present-data-from-rp1-and-rp2-clinical-programs-at-the-2024-asco-annual-meeting-12-month-results-from-the-ignyte-clinical-trial-of-rp1-plus-nivolumab-in-anti-pd-1-failed-melanoma-demonstrate-an-overall-response-rate-of-327-and-duration-of-response-consistent-with-the-previously-reported-6-month-data-from-ignyte-trial

-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma dem...

 replimune-group-inc-expects-enrollment-of-first-patients-in-phase-3-confirmatory-trial-of-rp1-in-advanced-melanoma-in-2h-2024

https://www.benzinga.com/secfilings/24/05/38870181/replimune-group-inc-general-corporate-statement-form8

 replimune-group-presented-the-interim-results-from-the-artacus-clinical-trial-of-rp1-monotherapy-in-solid-organ-and-hematopoietic-cell-transplant-recipients-with-skin-cancers-at-aacr-2024

In the study, treatment with RP1 as monotherapy, for up to 25 doses, resulted in an overall response rate (ORR) of 34.8 percent...

 replimune-group-q3-eps-077-beats-093-estimate

Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.9...

 barclays-maintains-overweight-on-replimune-group-lowers-price-target-to-13

Barclays analyst Peter Lawson maintains Replimune Group (NASDAQ:REPL) with a Overweight and lowers the price target from $50...

 crude-oil-moves-lower-autozone-profit-tops-views

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0...

 why-daktronics-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.

 dow-falls-100-points-ism-services-pmi-increases-in-november

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded...

 us-stocks-down-jm-smucker-posts-upbeat-earnings

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market openi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION